<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04797364</url>
  </required_header>
  <id_info>
    <org_study_id>REB20-0900</org_study_id>
    <nct_id>NCT04797364</nct_id>
  </id_info>
  <brief_title>Pharmacogenetic Supported Prescribing in Kids</brief_title>
  <acronym>PGx-SParK</acronym>
  <official_title>Pharmacogenetic Supported Prescribing in Kids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Implementation of pharmacogenetic testing for children and adolescents aged 7-17 who are&#xD;
      starting or changing psychiatric medication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children with moderate to severe mental health conditions (e.g. depression, anxiety, OCD) or&#xD;
      neurodevelopmental disorders (e.g., autism spectrum disorders, ADHD) are frequently&#xD;
      prescribed medications as either the sole form of treatment or in combination with&#xD;
      psychotherapy. However, up to 50% of these children will not respond or experience burdensome&#xD;
      adverse drug reactions to these medications. Current use of mental health-related medications&#xD;
      (e.g., antidepressants, antipsychotics) in children can be best described as a&#xD;
      trial-and-error process that can impact the well-being of those taking the medications and&#xD;
      their families at a considerable economic cost. However, this trial-and-error process could,&#xD;
      in part, be avoided through the application of pharmacogenetic testing, a specific type of&#xD;
      genetic testing that has the potential to improve drug efficacy and reduce the morbidity,&#xD;
      mortality and cost associated with adverse drug reactions. The aim of this project is to&#xD;
      implement and evaluate an evidence-based pharmacogenetic testing service to improve drug&#xD;
      treatment outcomes in children receiving mental health care.&#xD;
&#xD;
      Our objectives are to:&#xD;
&#xD;
        1. Implement Canada's first pharmacogenetics testing service to improve drug treatment&#xD;
           outcomes in children receiving mental health care.&#xD;
&#xD;
        2. Collect performance, outcome, and economic indicators related to the pharmacogenetics&#xD;
           testing service.&#xD;
&#xD;
        3. Establish a research platform for the discovery of new genetic and non-genetic markers&#xD;
           of drug treatment outcomes relevant to mental health care in children.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse drug reactions</measure>
    <time_frame>6-months</time_frame>
    <description>Relative change in adverse drug reaction frequency</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptom severity</measure>
    <time_frame>6-months</time_frame>
    <description>Relative change in symptom severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Healthcare utilization</measure>
    <time_frame>6-months</time_frame>
    <description>Relative change in healthcare utilization</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6000</enrollment>
  <condition>Mental Health Impairment</condition>
  <arm_group>
    <arm_group_label>Pharmacogenetic Testing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pharmacogenetic testing panel (CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A5, NUDT15, SLCO1B1, TPMT, VKORC1)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Pharmacogenetic Testing</intervention_name>
    <description>Participants will donate a 2ml (teaspoon) sample of saliva. DNA extracted from the saliva sample will be used for genotyping. Genotyping results will be translated into an interpretative clinical report using evidence-based software (Sequence2Script) developed by our group and delivered to the treating physician for use in their clinical decision-making. The report will contain genotyping results, predicted phenotype, and evidence-based drug selection and dosing recommendations relevant to the child's current and future care</description>
    <arm_group_label>Pharmacogenetic Testing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Medical records available&#xD;
&#xD;
          -  The initiation, change, dose adjustment, or augmentation of psychiatric medication(s)&#xD;
             is indicated&#xD;
&#xD;
          -  Treating psychiatrist, family physician, or pediatrician licensed in Alberta requests&#xD;
             pharmacogenetic testing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medically unstable or lacking capacity to provided informed consent&#xD;
&#xD;
          -  Unwillingness of child to provide saliva sample for genetic analysis&#xD;
&#xD;
          -  History of liver or bone marrow (hematopoietic cell) transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chad Bousman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laina McAusland, MSc</last_name>
    <phone>403-210-6353</phone>
    <email>psychpgxlab@ucalgary.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laina McAusland, MSc</last_name>
      <phone>403-210-6353</phone>
      <email>psychpgxlab@ucalgary.ca</email>
    </contact>
    <investigator>
      <last_name>Chad Bousman</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Arnold</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 9, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Calgary</investigator_affiliation>
    <investigator_full_name>Chad Bousman</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Child</keyword>
  <keyword>Adolescent</keyword>
  <keyword>Mental Health</keyword>
  <keyword>Psychiatry</keyword>
  <keyword>Pharmacogenetics</keyword>
  <keyword>Depression</keyword>
  <keyword>Anxiety</keyword>
  <keyword>OCD</keyword>
  <keyword>Psychosis</keyword>
  <keyword>Bipolar Disorder</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

